Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) emerged in the 2010s as one of the pioneers in leveraging artificial intelligence (AI) and advanced data analytics to transform drug discovery and development. Headquartered in Salt Lake City, Utah, the company has positioned itself at the forefront of the intersection between biotechnology and cutting-edge

Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpectedly well to treatment.

Just because it's not a household name doesn't mean it's not a magnificent investment.

Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments.

This group of companies reflects most of the industry's past, present, and future.

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading higher and trending. The company on Tuesday announced a reduction in personnel and infrastructure aimed at extending its cash runway.

The company now expects its projected cash runway to extend into the fourth quarter of 2027.

Shares of Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict molecular binding affinity with unmatched speed and accuracy.

A handful of industries are on the verge of explosive growth. These three companies are poised to gain the most.

While institutional money managers have released their Q1 holdings, so has the heart and soul of the AI revolution, NVIDIA. See which six stocks NVIDIA owns.